Biotech Market Dynamics
A significant downturn in the biotech sector saw stocks plummet 64%, with many companies trading below their cash reserves, indicating a market perception that their R&D was worthless. Despite this bleak outlook, early commercial companies with substantial revenues but no profits began to emerge as undervalued opportunities. As M&A activity picks up, the landscape for investment in biotech is evolving, revealing potential where the market had previously overlooked value.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
[REPLAY] Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Related Questions